Freely Filtered, a NephJC Podcast – Détails, épisodes et analyse

The draft order:

Sophia Ambruso

Nayan Arora

Swapnil Hiremath

AC Gomez

Joel Topf

Editor

Nayan Arora

Show Notes

Previous drafts:

2021 KDIGO Hypertension —Joel, Sophia, Swap, Nayan, Josh

2021 ASN Kidney Week Draft—Joel, Sophia, Swap, Nayan, Jennie

2022 The ISPD Peritonitis Guideline— Joel, Sophia, Swap, Nayan

2022 ASN Kidney Week Draft—Joel, Sophia, Swap, Nayan

2023 ASN Kidney Week Draft—Joel, Sophia, Swap, Nayan, AC, Josh

2024 KDIGO CKD Clinical Practice Guideline —Joel, Sophia, Swap, Nayan, Josh, AC

The guideline

The NephJC discussion Part 1 | Part 2

First Round

Sophia’s Pick 3.7.1 We recommend treating patients with type 2 diabetes (T2D), CKD, and an eGFR ≥20 ml/min per 1.73 m2 with an SGLT2i (1A).

Not Nayan’s Pick 3.7.3: We suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).

Nayan’s Pick 2.2.1: In people with CKD G3–G5, we recommend using an externally validated risk equation to estimate the absolute risk of kidney failure (1A).

A birdie told me there will not be a Tangri KFRE vs the World debate at Kidney Week

The action points based on absolute risk results:

Practice Point 2.2.1: A 5-year kidney failure risk of 3%–5% can be used to determine need for nephrology referral in addition to criteria based on eGFR or urine ACR, and other clinical considerations.

Practice Point 2.2.2: A 2-year kidney failure risk of >10% can be used to determine the timing of multidisciplinary care in addition to eGFR-based criteria and other clinical considerations.

Practice Point 2.2.3: A 2-year kidney failure risk threshold of >40% can be used to determine the modality education, timing of preparation for kidney replacement therapy (KRT) including vascular access planning or referral for transplantation, in addition to eGFR-based criteria and other clinical considerations.

Swap’s Pick 3.15.1.1: In adults aged ‡50 years with eGFR <60 ml/min per 1.73 m2 but not treated with chronic dialysis or kidney transplantation (GFR categories G3a–G5), we recommend treatment with a statin or statin/ezetimibe combination (1A).

AC’s Pick 3.7.2: We recommend treating adults with CKD with an SGLT2i for the following (1A):

eGFR ≥20 ml/min per 1.73 m2 with urine ACR ≥200 mg/g (≥20 mg/mmol), or

heart failure, irrespective of level of albuminuria. (1A)

Joel’s Pick 3.10.1: In people with CKD, consider use of pharmacological treatment with or without dietary intervention to prevent development of acidosis with potential clinical implications (e.g., serum bicarbonate <18 mmol/l in adults).

Practice Point 3.10.2: Monitor treatment for metabolic acidosis to ensure it does not result in serum bicarbonate concentrations exceeding the upper limit of normal and does not adversely affect BP control, serum potassium, or fluid status.

Freely Filtered 061: Bicarb in Transplant with Nav Tangri

Second Round

Joel’s Pick 3.3.1.1: We suggest maintaining a protein intake of 0.8 g/kg body weight/d in adults with CKD G3–G5 (2C).

Practice points related to protein intake:

3.3.1.1: Avoid high protein intake (>1.3 g/kg body weight/d) in adults with CKD at risk of progression.

3.3.1.2: In adults with CKD who are willing and able, and who are at risk of kidney failure, consider prescribing, under close supervision, a very low–protein diet (0.3–0.4 g/kg body weight/d) supplemented with essential amino acids or ketoacid analogs (up to 0.6 g/kg body weight/d).

3.3.1.3: Do not prescribe low- or very low–protein diets in metabolically unstable people with CKD.

AC’s Pick 3.9.1: In adults with T2D and CKD who have not achieved individualized glycemic targets despite use of metformin and SGLT2 inhibitor treatment, or who are unable to use those medications, we recommend a long-acting GLP-1 RA (1B).

Swapnil’s Pick Practice Point 5.4.1: Initiate dialysis based on a composite assessment of a person’s symptoms, signs, QoL, preferences, level of GFR, and laboratory abnormalities.

IDEAL Trial: A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis NEJM

Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study NephJC

Nayan’s Pick Practice Point 1.1.4.2: Use tests to establish a cause based on resources available (Table 6b).

Sophia’s Pick Practice Point 1.1.1.2: Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.

Joel’s cystatin C Tweet

The cystatin C guideline recommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C– based estimated glomerular filtration rate [eGFRcr-cys]) (1B).

Nayan’s additional thoughts. He is not a fan of Practice Points 3.6.4 and 3.6.5

Practice Point 3.6.4 Continue ACEi or ARB therapy unless serum creatinine rises by more than 30% within 4 weeks following initiation of treatment or an increase in dose.

and

Practice Point 3.6.5: Consider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate [eGFR] <15 ml/min per 1.73 m2).

Tubular Secretion

Swap The Murderbot Diaries by Martha Wells

Nayan Searching for Hobey Baker Narrated by David Duchovny

AC Rosie Revere, Engineer

Sophia Bassnectar

How to fix the Apple Music automatically playing when you connect to bluetooth.

Joel The Veil with Elizabeth Moss

The Filtrate:

Joel Topf

Josh Waitzman

With Special Guest:

Brad Rovin (@BradRovin) Chief of nephrology at The Ohio State University Wexner Medical Center, one of the authors of the Nefigard trial.

Koyal Jain (@koyaljainMD) Program director of the GN Fellowship at University of North Carolina

Roger Rodby (@NephRodby) Associate program director of the Rush University Nephrology Fellowship

Editor

Sophia Ambruso

Show Notes

The manuscript (The Lancet | PubMed | NephJC)

The Results of Part A (Kidney Int | PubMed)

Edmund (Ed) Louis memorium by Steve Korbet in KI

Steve Korbet Do not miss this tweet

TESTING Freely Filtered #48 with Sean Barbour

Iptapocan at the World Congress of Nephrology: WCN24-1506 Efficacy And Safety Of Iptacopan In Patients With IgA Nephropathy: Interim Results From The Phase 3 APPLAUSE-IgAN Study

FDA and mandatory post-marketing studies. What happens when the study is negative (or not completed) (UNDARK)

Who should treat lupus nephritis: rheumatologists or nephrologists? (Nature Reviews Nephrology)

Protein and albumin-to-creatinine ratios in random urines accurately predict 24 h protein and albumin loss in patients with kidney disease (PubMed)

MEST Scores in NephJC

Risk scores in IgAN in NephJC

Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome (NDT)

Tarpeyo pills 4 mg. Four pills once a day. (WellRx has a picture of the pills)

IgA nephropathy in African Americans: uncommon but possible (PubMed Central)

Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don’t Know (PubMed Central)

Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy (JAMA Network Open)

Tubular Secretions

Joel: Constellation on Apple TV (Wikipedia). Not good. Dune audio books are excellent. (Audible)

Josh: Podcasts about donating a kidney

One Is Enough Podcast (National Kidney Registry)

Donor Diaries (National Kidney Donation Organization)

Roger Iceland (Wikipedia)

Koyal India (Wikipedia)

Brad Fishing in Dubai

The Filtrate:

Joel Topf

Swapnil Hiremath

Sophia Ambruso

AC Gomez

With Special Guest:

Amit Garg (@AmitXGarg) Nephrologist at Western University, London, and lead PI of the EnAKT LKD trial. 

Susan Q. McKenzie (LinkedIn) Co-Founder & Chair, Transplant Ambassador Program. President of the Kidney Patient and Donor Alliance of Canada.

Editor:

Joel Topf

Show Notes:

Late Braking and High Impact Clinical Trial press release

JAMA Internal Medicine

MyTEMP trial Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial (PubMed | NephJC | Freely Filtered)

Transplant is cheaper! An economic assessment of contemporary kidney transplant practice (PDF)

Transplant is better! Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: systematic review and meta-analysis (PubMed)

Transplant disparities Association of Race and Ethnicity With Live Donor Kidney Transplantation in the United States From 1995 to 2014 (PubMed)

MUC1 Kidney Disease Autosomal Dominant Tubulointerstitial Kidney Disease: An Emerging Cause of Genetic CKD (Kidney International Reports)

This study has all the adjectives: “We conducted a pragmatic, two-arm, parallel-group, open-label, registry-based, superiority, cluster- randomized clinical trial.”

Explore Transplant by Amy Waterman, PhD

Transplant Ambassador Program

Kidney Failure Risk Equation A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure (JAMA | Calculator)

The complete protocol A Quality Improvement Intervention to Enhance Access to Kidney Transplantation and Living Kidney Donation (EnAKT LKD) in Patients With Chronic Kidney Disease: Clinical Research Protocol of a Cluster-Randomized Clinical Trial (PDF)

Pre-published statistical plan Enhance Access to Kidney Transplantation and Living Kidney Donation (EnAKT LKD): Statistical Analysis Plan of a Registry-Based, Cluster-Randomized Clinical Trial (PubMed)

Hawthorne effect (Wikipedia)

The Advancing American Kidney Health Initiative “Aim for 80% of new American ESRD patients in 2025 receiving either home dialysis or a transplant” (NKF)

Tubular Secretions

Swapnil The Time Travelers Wife by Audrey Niffenegger (Wikipedia) and HBO movie of the same name (Wikipedia).

Sophia The Wheel of Time streaming on Amazon (Wikipedia) based on the series of books of the same name by Robert Jordan and Brandon Sanderson.

Susan The Woman Who Loved Giraffes movie (Website)

Amit Canadians cannot get Visas to visit India (Reuters)

AC Eagles are good at Football (Fox Sports) and Alport Connect Meeting in San Diego (Alport Syndrome Foundation Website)

Joel Live podcast recording at Kidney Week (NephJC)

The Filtrate:

Joel Topf

Jennie Lin

Josh Waitzman

With Special Guest:

AC Gomez MedPeds nephrology fellow at Mass General/Brigham and Boston Children’s | Twitter

Gentian Hall Assistant Professor of Medicine Duke Department of Medicine

Editor:

Sophia Ambruso

Show Notes:

APOL1 review by the OG Scientists APOL1 Nephropathy: From Genetics to Clinical Applications

MYH9 and APOL1 connection: The population genetics of chronic kidney disease: insights from the MYH9–APOL1 locus

Martin Pollack Lab

Vertex Lab

Worldwide Frequencies of APOL1 Renal Risk Variants (NEJM)

Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function

End-Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1

Apolipoprotein L1 Risk Variants Associate with Systemic Lupus Erythematosus-Associated Collapsing Glomerulopathy

HEK293 Cells Wikipedia

Tubular Secretions

Josh: From Serial and the New York Times: The Retrievals

Jennie: Marathon induced hyponatremia (NEJM)
Donate to the NKF of Illinoise in honor of Jennie’s really long run
Donate to New England Donor Services in honor of Josh’s much shorter ruin

Gentian: Vivien Thomas wikipedia. HBO Movie: Something the Lord Made

AC: Talking to the FDA about SGLT2i Tweet

Joel: NephJC 2023 Fund drive

Bicarbonate did not slow the loss of GFR in this well done Swiss, single-blind study of transplant patients.

The Filtrate:

Joel Topf

Nayan Arora

Swapnil Hiremath

Pirya Yenebere

With Special Guest:

Nav Tangri nephrologist and epidemiology at the University of Manitoba

Editor:

Nayan Arora

Show Notes:

Arsenal FC

The London study that kicked it all off!

de Brito-Ashurst, I., Varagunam, M., Raftery, M. J., & Yaqoob, M. M. (2009). Bicarbonate supplementation slows progression of CKD and improves nutritional status. Journal of the American Society of Nephrology: JASN, 20(9), 2075–2084.

The multi center (but unblinded) UBI Study with mortality benefit!

Di Iorio, B. R., Bellasi, A., Raphael, K. L., Santoro, D., Aucella, F., Garofano, L., Ceccarelli, M., Di Lullo, L., Capolongo, G., Di Iorio, M., Guastaferro, P., Capasso, G., & UBI Study Group. (2019). Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. Journal of Nephrology, 32(6), 989–1001.

The BiCARB Study: Double blinded and negative

BiCARB study group. (2020). Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial. BMC Medicine, 18(1), 91.

The initial Veverimer Study

Wesson, D. E., Mathur, V., Tangri, N., Stasiv, Y., Parsell, D., Li, E., Klaerner, G., & Bushinsky, D. A. (2019). Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. In The Lancet (Vol. 394, Issue 10196, pp. 396–406). doi.org/10.1016/s0140-6736(19)31388-1

The Valor CKD trial is still unpublished. But here is the press release.

VALOR-CKD design manuscript

The study of the night: Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomized, single-blind, placebo-controlled, phase 3 trial

NephJC | PubMed | Lancet

Alkali with normal bicarb? Sure, take a look at: Goraya, N., Simoni, J., Jo, C., & Wesson, D. E. (2012). Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney International, 81(1), 86–93.

Metforminator!

The BASE Trial: Raphael, K. L., Isakova, T., Ix, J. H., Raj, D. S., Wolf, M., Fried, L. F., Gassman, J. J., Kendrick, C., Larive, B., Flessner, M. F., Mendley, S. R., Hostetter, T. H., Block, G. A., Li, P., Middleton, J. P., Sprague, S. M., Wesson, D. E., & Cheung, A. K. (2020). A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. Journal of the American Society of Nephrology: JASN, 31(1), 161–174.

Tubular Secretions

Swap The Three-Body Problem (novel) | Netflix

Nayan Women’s World Cup

Tangri English Premier Soccer and Inflation

Priya Silo on Apple TV

Joel Live Podcast recording at ASN Kidney

The Filtrate:

Joel Topf

Nayan Arora

Sophia Ambruso

With Special Guest:

Boback Ziaeian @boback Assistant Professor of Medicine David Geffen School of Medicine at UCLA. His Google Schoolar page is better than yours.

And returning for her fourth time (why do we keep inviting her back?)
Sadiya Khan @heartDocSadiya Assistant Professor of Medicine (Cardiology) and Preventative Medicine at Northwestern Feinberg School of Medicine. Link

Editor:

Priya Yenebere

Show Notes:

Diuretic Therapy review by. Craig Brater NEJM

The manuscript in JAMA | NephJC

Metoprolol vs Carvedilol: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial (Lancet)

EMPULSE: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (Nature Medicine)

Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure The ASTRONAUT Randomized Trial

Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure The EVEREST Outcome Trial

Sophia ended up placing fifth in NephMadness 2023. (Link)

Joel finished 697th

After winning in the opening round, Northwestern lost to UCLA, in the second round of the March Madness tournament, 68-63.

Torsemide to furosemide equivalents

CardioMems positive trial: Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial (The Lancet)

CardioMems negative trial: Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial (The Lancet)

Estimation of the Absolute Risk of Cardiovascular Disease and Other Events: Issues With the Use of Multiple Fine-Gray Subdistribution Hazard Models (Circulation)

Torasemide in chronic heart failure: results of the TORIC study (PubMed)

Tubular Secretions

Nayan: Louise Penny A World of Curiosities: A Novel (Amazon)

Sadiya: Ted Lasso season three

Sophia:The Last of Us on HBO and SNL skit Mario Cart as Prestige Drama

Boback: Duolingo for Japanese

The Filtrate:

Joel Topf

Swapnil Hiremath

Josh Waitzman

Nayan Arora

Sophia Ambruso

With Special Guest:

Megan Prochaska Assistant professor of medicine at University of Chicago

John Asplin Medical Director Consultant LithoLink (Twitter)

Editor:

Joel Topf

Show Notes:

The LithoLink website

Stone Camp tweet

Prevention of Repeated Episodes of Kidney Stones in Adults: A Clinical Practice Guideline From the American College of Physicians (link)

NOSTONE in the NEJM and NephJC

Fred Coe Google Scholar | YouTube | Blog

Hypercalcuria. Curhan et al. 24-h uric acid excretion and the risk of kidney stones PubMed

EQUIL2 software to evaluate urinary super saturation

Anna Zisman Racial Differences in Risk Factors for Kidney Stone Formation (CJASN)

Potassium Citrate on GoodRx

Moonstone Nutrition

Potassium and citrate by Fred Coe (blog)

Thiazide Diuretics and Fracture Risk: A Systematic Review and Meta‐Analysis of Randomized Clinical Trials (PubMed)

Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria by Coe et al (PubMed)

NHANES 24-hour urine Na (Abstract)

Kidney Stone risk is reduced with empagliflozin (PubMed)

Prospective trial to determine the effect of SGLT2i on urinary supersaturation (BMJ Open)

GLP agonists and kidney stone risk

Tubular Secretions

Swap: Star Wars: Thrawn Series by Timothy Zahn (Penguin Random House)

Josh: Little League

Megan: Renal related podcasts

Sophia Renal Stone Camp and ABCKidney.com

Nayan: Ted Lasso Robert Galbraithand The Comoran Strike Novels (home page)

John: Fred Coe’s Blog

Joel: Spiderman across the Spider-Verse (Wikipedia)

The Filtrate:

Joel Topf

Swapnil Hiremath

Josh Waitzman

Sophia Ambruso

With Special Guest:

Anna Vinakova Associate Professor of Medicine at Virginia Commonwealth University. NephMadness Executive.

Vanuja Java is a transplant nephrologist at Washington University in St. Louis, MO. Her research involves functional characterization of genetic variants in complement-mediated diseases. She co-chairs the ClinGen complement gene curation expert panel.

Editor:

Sophia Ambruso

Show Notes:

#NephMadness 2023: Thrombotic Microangiopathy Region

TMA Review article in the NEJM from 2014: Syndromes of Thrombotic Microangiopathy

Dr. Anuja Java Co-chairs Working Group in an International Committee for Revising aHUS Nomenclature

Nephrology Secrets 4th Edition at Amazon

University of Iowa Genetic testing for aHUS

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study. KI reports. This is the Netherlands study. They used home urine dipsticks to monitor for relapses.

Clinical promise of next-generation complement therapeutics Nature reviews. Drug Discovery

NephMadness Podcrawl

Tubular Secretions

Swap: Neuromancer and the works of William Gibson (@GreatDismal)

Sophia: The Magicians on Netflix

Anna: Recommends nephrology. Says it is awesome.

Anuja: Dope Sick on Hulu and Women in Nephrology mentor program

Josh: Mobituaries with Mo Rocca. Specifically “Death of a Banana”

Joel: Ivory by TapBot

Welcome to the NephMadness PodCrawl

The idea behind a podcrawl is for a variety of podcasts to coordinate on timing and topic to push a theme and get each other’s listeners to explore all of the podcasts. One of the first goals behind NephMadness was to build a community and in the early years of Twitter, NephMadness was central to the formation of #NephTwitter and defining the ethos that makes our online community kind, intelligent, vibrant, and interesting. The NephMadness Podcrawl hopes to inspire and grow the nephrology podcast community in the same way. For 2023, our second year,  the PodCrawl has assembled the Avengers of Medical Pods!

Go to NephMadness.com/podcrawl for more information and links to all of the podcasts!

The Curbsiders gets the skinny on mineralcorticoid receptor antagonists

Core IM will be covering Kidney Transplant in their classic Five Pearl format

The CardioNerds will be covering the effect of Heart Failure Devices on Kidney Health

Freely Filtered will try to understand thrombotic microangiopathy

ISN Global Kidney Care goes deep on IgA nephropathy

The Cribsiders look at transitions, first the Peditrics to Adult nephrology transition and then from living to death with palliative nephrology 

Fellow on Call will be covering Onconephrology

And finally, The Nephron Segment looks at Transgender Health and CKD

The Filtrate:

Joel Topf

Swapnil Hiremath

Nayan Arora

Sophia Ambruso

With Special Guest:

Amit Garg @AmitXGarg, Nephrologist at Western University, London, and lead PI of the MYTEMP trial. 

Editor:

Joel Topf

Show Notes:

MyTEMP in pubmed: Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial

MyTEMP Summary on NephJC 

It’s really cold in Ontario

The NephTrials blog summary on Pragmatic Trials

The pragmatic TiME trial on longer time on dialysis (ahem, sabotaged by site investigators like Joel who cut dialysate time) Dember et al in JASN

Poor quality of trial data preceding MyTEMP, a systematic review from Mustafa et al in JASN 

The 2007 European Best Practice Guideline (EBPG) from 2007, recommending “Cool dialysate temperature dialysis (35–36°C) or isothermic treatments by blood temperature controlled feedback should be prescribed in patients with frequent episodes of IDH (Evidence level I).” in NDT

47% of centres from a DOPPS study of 273 centers routinely use of lower dialysate temperature, Dasgupta et al in JASN

How do you convert from C to F? Almanac.com (35.5 C is 96.9 F; 37 C is 98.6 F)

More on the rationale and design of MyTEMP: Al-Jaishi et al in CJKHD

How big is 4.3 million (the number of hemodialysis treatments in MyTEMP)? Very big indeed.

NephJC discussion of another cluster RCT and granular data only on a subset SSASS 

Participants in dialysis clinical trials are not representative of the real world dialysis cohorts, Smyth et al in JAMA Int Med

Peritoneal dialysis numbers in Ontario are high, Blake et al in PDI, though with ~ 60% CVC rates, Blake et al in Kidney360

Dialysate Magnesium #DreamRCT from Swap, NephTrials discussion of DialMag

Statistical analysis plan of MyTEMP, Dixon et al in CJKHD

Tubular Secretions

Swap: Watch Everything, Everywhere All At Once on Prime

Nayan: Read The Midnight Ride from Ben Mezrich (brother of Josh Mezrich from the NephJC Summer Book Club 2021)

Sophia: Making nephrology education fun at the UC Denver

Amit: The wrestling team at Western U from 1990-91

Joel: House of the Dragon on HBO Max